Literature DB >> 23825314

High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer.

Ludovic Martinet1, Thomas Filleron, Sophie Le Guellec, Philippe Rochaix, Ignacio Garrido, Jean-Philippe Girard.   

Abstract

Blood vessels and tumor angiogenesis are generally associated with tumor growth and poor clinical outcome of cancer patients. However, we recently discovered that some blood vessels present within the tumor microenvironment can be associated with favorable prognosis. These vessels, designated tumor high endothelial venules (HEVs), appear to facilitate tumor destruction by allowing high levels of lymphocyte infiltration into tumors. In this study, we investigated the mechanisms regulating HEV blood vessels in human breast cancer. We found that lymphotoxin β was overexpressed in tumors containing high densities of HEVs (HEV(high)) and correlated to DC-LAMP, a marker of mature DCs. DCs were the main producers of lymphotoxin β in freshly resected HEV(high) breast tumor samples, and the density of DC-LAMP(+) DCs clusters was strongly correlated with the density of tumor HEVs, T and B cell infiltration, and favorable clinical outcome in a retrospective cohort of 146 primary invasive breast cancer patients. Densities of tumor HEVs and DC-LAMP(+) DCs were strongly reduced during breast cancer progression from in situ carcinoma to invasive carcinoma, suggesting that loss of tumor HEVs is a critical step during breast cancer progression. Finally, an increase in the infiltration of regulatory T cells was observed in HEV(high) breast tumors, indicating that tumor HEVs can develop in the presence of regulatory T cells. Together, our results support a key role for DCs and DC-derived lymphotoxin in the formation of tumor HEVs. These findings are important because novel therapeutic strategies based on the modulation of tumor HEVs could have a major impact on clinical outcome of cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23825314     DOI: 10.4049/jimmunol.1300872

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.

Authors:  Xia Liu; Julia Y S Tsang; Thazin Hlaing; Jintao Hu; Yun-Bi Ni; Siu Ki Chan; Sai Yin Cheung; Gary M Tse
Journal:  Oncologist       Date:  2017-07-12

Review 3.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

Review 4.  Lymphatic vessels and tertiary lymphoid organs.

Authors:  Nancy H Ruddle
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 5.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

6.  Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.

Authors:  Yu Zhang; Fei Wang; Hao-Ran Sun; Ya-Kai Huang; Jian-Peng Gao; Hua Huang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-23       Impact factor: 4.553

7.  Presence of tumour high-endothelial venules is an independent positive prognostic factor and stratifies patients with advanced-stage oral squamous cell carcinoma.

Authors:  Anna M Wirsing; Oddveig G Rikardsen; Sonja E Steigen; Lars Uhlin-Hansen; Elin Hadler-Olsen
Journal:  Tumour Biol       Date:  2015-09-17

Review 8.  Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.

Authors:  J David Peske; Amber B Woods; Victor H Engelhard
Journal:  Adv Cancer Res       Date:  2015-06-01       Impact factor: 6.242

9.  High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers.

Authors:  Hee Jin Lee; Joo Young Kim; In Hye Song; In Ah Park; Jong Han Yu; Jin-Hee Ahn; Gyungyub Gong
Journal:  Virchows Arch       Date:  2015-10-07       Impact factor: 4.064

Review 10.  Tertiary lymphoid structures in the era of cancer immunotherapy.

Authors:  Catherine Sautès-Fridman; Florent Petitprez; Julien Calderaro; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.